Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Closed
    Phase
    Accrual
    5%
    SWOG Clinical Trial Number
    S1900B

    A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
    Status Notes
    S1900B will close to accrual April 30, 2021, effective 12:00 pm PST.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    02-10-2020
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1900C

    A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)
    Status Notes
    S1900C closed to accrual December 18, 2020.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    01-16-2020
    Closed
    12-18-2020
    Open
    Phase
    Accrual
    32%
    SWOG Clinical Trial Number
    S1827

    MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
    Status Notes
    This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
    Research Committee(s)
    Lung Cancer
    Activated
    01-10-2020
    ClinicalTrials.gov Registry Number
    04155034
    Open
    Phase
    Accrual
    34%
    SWOG Clinical Trial Number
    S1922

    Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
    Status Notes
    The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-16-2019
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1826

    A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
    Status Notes
    Temporary Closure: Effective Wednesday, October 05, 2022, 12:00 p.m. Pacific Time
    Research Committee(s)
    Lymphoma
    Activated
    07-19-2019
    Closed
    12-01-2022
    ClinicalTrials.gov Registry Number
    03907488
    Open
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1803

    Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
    Status Notes
    This study is re-opened to patient accrual effective 11/15/2023.
    Research Committee(s)
    Myeloma
    Activated
    06-27-2019
    Closed
    Phase
    Accrual
    3%
    SWOG Clinical Trial Number
    S1916

    Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
    Status Notes
    This study is permanently closed effective September 16, 2020.
    Research Committee(s)
    Cancer Care Delivery
    Activated
    06-11-2019
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1800A

    A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
    Status Notes
    S1800A closed to accrual November 16, 2020.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    05-17-2019
    Closed
    11-16-2020
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1806

    Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
    Status Notes
    Study permanently closed to accrual as of 04/01/2024, noon PST.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    04-19-2019
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1714

    A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
    Status Notes
    S1714 will permanently close to accrual on November 15, 2021 at 12:00 pm PST.
    Research Committee(s)
    Symptom Control and Quality of Life
    Breast Cancer
    Lung Cancer
    Early Therapeutics & Rare Cancers
    Activated
    03-01-2019
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1600

    A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
    Status Notes
    S1600 study will be permanently closed to accrual, effective 10/20/2023.
    Research Committee(s)
    Symptom Control and Quality of Life
    Genitourinary Cancer
    Activated
    02-21-2019
    Closed
    10-20-2023
    ClinicalTrials.gov Registry Number
    NCT03757949
    Closed
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S1614

    Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors
    Status Notes
    Active 2/21/19
    Reactivation, effective 7/1/21
    Research Committee(s)
    Symptom Control and Quality of Life
    Breast Cancer
    Gastrointestinal Cancer
    Genitourinary Cancer
    Lung Cancer
    Melanoma
    Activated
    02-21-2019
    Closed
    11-15-2022
    ClinicalTrials.gov Registry Number
    03887702
    Closed
    Phase
    Accrual
    73%
    SWOG Clinical Trial Number
    S1900A

    A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA 1/2 MUTATION STAGE IV NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
    Status Notes
    S1900A is permanently closed to accrual, effective 2/1/21.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    01-29-2019
    ClinicalTrials.gov Registry Number
    NCT03845296
    Open
    Phase
    SWOG Clinical Trial Number
    LUNGMAP

    A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
    Status Notes
    LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    01-28-2019
    ClinicalTrials.gov Registry Number
    NCT03851445
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1801

    A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.
    Status Notes
    Permanent Closure: Effective May 5, 2022, at 11:59 p.m. Pacific Time.
    Research Committee(s)
    Melanoma
    Activated
    12-06-2018
    Closed
    05-05-2022
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1815

    A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Status Notes
    This study permanently closed to accrual effective 2/15/21.
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-03-2018
    Closed
    02-15-2021
    Open
    Phase
    Accrual
    62%
    SWOG Clinical Trial Number
    S1802

    Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
    Status Notes
    Activated 9/17/18.
    Research Committee(s)
    Genitourinary Cancer
    Other
    Symptom Control and Quality of Life
    Activated
    09-17-2018
    Open
    Phase
    Accrual
    51%
    SWOG Clinical Trial Number
    S1706

    A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
    Status Notes
    Activation, Effective 9/12/2018, 2:00 pm CT
    Research Committee(s)
    Breast Cancer
    Activated
    09-12-2018
    ClinicalTrials.gov Registry Number
    NCT03598257
    Closed
    Phase
    Accrual
    32%
    SWOG Clinical Trial Number
    S1701

    A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
    Status Notes
    Permanent Closure - Effective 09/29/2022
    Research Committee(s)
    Lung Cancer
    Activated
    08-09-2018
    Closed
    09-29-2022
    ClinicalTrials.gov Registry Number
    03694002
    Closed
    Phase
    Accrual
    96%
    SWOG Clinical Trial Number
    S1712

    A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
    Status Notes
    The study is closed to accrual effective 10/20/2022.
    Research Committee(s)
    Leukemia
    Activated
    07-20-2018
    ClinicalTrials.gov Registry Number
    NCT03654768